Pictet Asset Management (UK)’s Intellia Therapeutics NTLA Stock Holding History

Pictet Asset Management (UK)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$65.1M	Sell	401,815 -260,992	-39%	-$20.3M	0.07%	298
2021 Q1	$53.2M	Buy	662,807 +659,107	+17,814%	+$44.2M	0.06%	316
2020 Q4	$201K	Buy	+3,700	New	+$134K	﹤0.01%	1611
2018 Q4	–	Sell	-142,084	Closed	-$4.07M	–	1006
2018 Q3	$4.07M	Sell	142,084 -1,691	-1%	-$49.2K	0.01%	785
2018 Q2	$3.93M	Buy	+143,775	New	+$3.48M	0.01%	712

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Pictet Asset Management (UK)'s NTLA Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Intellia Therapeutics (NTLA) stake by 39% in Q2 2021, selling an estimated $20.3M and leaving 401,815 shares worth $65.1M. The position accounts for 0.07% of the portfolio, ranked #298.

Pictet Asset Management (UK) first reported a position in NTLA in Q2 2018 and has held it in 5 quarters since. 335 funds tracked by Wall St. Rank hold NTLA as of Q2 2021.

Pictet Asset Management (UK) held 401,815 shares of Intellia Therapeutics worth $65.1M as of Q2 2021.
Pictet Asset Management (UK) sold 260,992 Intellia Therapeutics shares in Q2 2021, an estimated $20.3M.
Intellia Therapeutics made up 0.07% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #298 holding.
Pictet Asset Management (UK) first reported a position in Intellia Therapeutics in Q2 2018 and has held it in 5 quarters since.
335 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.